27/08/08
First half year 2008 : a 19% increase in operating profit and net profit
The Board of Directors, meeting today under the chairmanship of Albert...
27/08/08
Oralair® Grasses 300 IR : Highly positive clinical results in a pharmacodynamic study conducted in an allergen challenge chamber
Stallergenes S.A. announces the highly positive results of a new study...
24/06/08
Obtention of the market authorization in Germany for Oralair® Grasses
Stallergenes has been granted with the market authorization in Germany for...
| We comply with the HONcode standard for trustworthy health information: verify here. |
Last update: 21/08/2008
Stallergenes is an European biopharmaceutical laboratory specialising in the treatment by desensitisation of allergy-related respiratory conditions.
The Group's activities focus on research into allergy, and the development, production and distribution of allergen extracts for the curative treatment of allergic rhinitis and asthma.
Visit the investors website
